4.8 Article

Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2

期刊

BMC MEDICINE
卷 20, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12916-022-02252-0

关键词

Ad26; COV2; S; BNT162b2; mRNA-1273; Antibody binding; Neutralizing antibodies; Antigen-specific B cells; Antigen-specific T cells

资金

  1. NIH [75N9301900065]

向作者/读者索取更多资源

This study compared the immunogenicity of Ad26.COV2.S and mRNA vaccines and found that mRNA vaccines elicited stronger humoral immune responses, while there were no significant differences in antigen-specific B cell and T cell responses between the two vaccine classes.
Background Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. Main body We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. Conclusions A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据